CG Oncology Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 142

Employees

  • Stock Symbol
  • CGON

Stock Symbol

  • Share Price
  • $81.90
  • (As of Thursday Closing)

CG Oncology General Information

Description

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Contact Information

Formerly Known As
Cold Genesys
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 400 Spectrum Center Drive
  • Suite 2040
  • Irvine, CA 92618
  • United States
+1 (714)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 400 Spectrum Center Drive
  • Suite 2040
  • Irvine, CA 92618
  • United States
+1 (714)

CG Oncology Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CG Oncology Stock Performance

As of 19-Nov-2026, CG Oncology’s stock price is $81.90. Its current market cap is $7.32B with 89.3M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$81.90 $80.00 $37.01 - $93.95 $7.32B 89.3M 1.22M -$2.76

CG Oncology Financials Summary

As of 30-Sep-2026, CG Oncology has a trailing 12-month revenue of $6.17M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 5,264,257 2,676,238 1,642,985
Revenue 6,166 4,040 1,139 204
EBITDA (261,247) (189,481) (114,631) (55,494)
Net Income (237,458) (160,995) (88,039) (48,607)
Total Assets 1,046,670 791,592 754,797 199,301
Total Debt 9,237 7,021 238 461
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CG Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CG Oncology‘s full profile, request access.

Request a free trial

CG Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore CG Oncology‘s full profile, request access.

Request a free trial

CG Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product
Drug Discovery
Irvine, CA
142 As of 2025

Emeryville, CA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CG Oncology Competitors (35)

One of CG Oncology’s 35 competitors is Nexoplex bio, a Formerly VC-backed company based in Emeryville, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nexoplex bio Formerly VC-backed Emeryville, CA
Senti Biosciences Holdings Formerly VC-backed South San Francisco, CA
AVEO Oncology Formerly VC-backed Boston, MA
Replimune Formerly VC-backed Woburn, MA
Oncorus Formerly VC-backed Andover, MA
You’re viewing 5 of 35 competitors. Get the full list »

CG Oncology Patents

CG Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026102329-A1 Methods and compositions for predicting response to oncolytic virotherapy Pending 08-Nov-2024
WO-2026096653-A1 Methods of treating non-muscle invasive bladder cancer Pending 31-Oct-2024
WO-2025251014-A1 Methods and compositions for biomarker-guided bladder cancer therapy Pending 31-May-2024
WO-2025251003-A1 Methods of treating bladder cancer using an oncolytic virus Pending 31-May-2024
WO-2025251009-A1 Methods of treating bladder cancer using an oncolytic virus and a transduction-enhancing agent Pending 31-May-2024 C12N15/86
To view CG Oncology’s complete patent history, request access »

CG Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CG Oncology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CG Oncology‘s full profile, request access.

Request a free trial

CG Oncology ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

36.7 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view CG Oncology’s complete esg history, request access »

CG Oncology FAQs

  • When was CG Oncology founded?

    CG Oncology was founded in 2010.

  • Where is CG Oncology headquartered?

    CG Oncology is headquartered in Irvine, CA.

  • What is the size of CG Oncology?

    CG Oncology has 142 total employees.

  • What industry is CG Oncology in?

    CG Oncology’s primary industry is Drug Discovery.

  • Is CG Oncology a private or public company?

    CG Oncology is a Public company.

  • What is CG Oncology’s stock symbol?

    The ticker symbol for CG Oncology is CGON.

  • What is the current stock price of CG Oncology?

    As of 19-Nov-2026 the stock price of CG Oncology is $81.90.

  • What is the current market cap of CG Oncology?

    The current market capitalization of CG Oncology is $7.32B.

  • What is CG Oncology’s current revenue?

    The trailing twelve month revenue for CG Oncology is $6.17M.

  • Who are CG Oncology’s competitors?

    Nexoplex bio, Senti Biosciences Holdings, AVEO Oncology, Replimune, and Oncorus are some of the 35 competitors of CG Oncology.

  • What is CG Oncology’s annual earnings per share (EPS)?

    CG Oncology’s EPS for 12 months was -$2.76.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process